Literature DB >> 28710589

Primary Care Physician Perspectives on Barriers to Statin Treatment.

Rikki M Tanner1, Monika M Safford2, Keri L Monda3, Benjamin Taylor3, Ronan O'Beirne4, Melanie Morris4, Lisandro D Colantonio5, Ricardo Dent6, Paul Muntner5, Robert S Rosenson7.   

Abstract

PURPOSE: Discontinuation of statin therapy represents a major challenge for effective cardiovascular disease prevention. It is unclear how often primary care physicians (PCPs) re-initiate statins and what barriers they encounter. We aimed to identify PCP perspectives on factors influencing statin re-initiation.
METHODS: We conducted six nominal group discussions with 23 PCPs from the Deep South Continuing Medical Education network. PCPs answered questions about statin side effects, reasons their patients reported for discontinuing statins, how they respond when discontinuation is reported, and barriers they encounter in getting their patients to re-initiate statin therapy. Each group generated a list of responses in round-robin fashion. Then, each PCP independently ranked their top three responses to each question. For each PCP, the most important reason was given a weight of 3 votes, and the second and third most important reasons were given weights of 2 and 1, respectively. We categorized the individual responses into themes and determined the relative importance of each theme using a "percent of available votes" metric.
RESULTS: PCPs reported that side effects, especially muscle/joint-related symptoms, were the most common reason patients reported for statin discontinuation (47% of available votes). PCPs reported statin re-challenge as their most common response when a patient discontinues statin use (31% of available votes). Patients' fear of side effects was ranked as the biggest challenge PCPs encounter in getting their patients to re-initiate statin therapy (70% of available votes).
CONCLUSION: PCPs face challenges getting their patients to re-initiate statins, particularly after a patient reports side effects.

Entities:  

Keywords:  Discontinuation; Nominal groups; Qualitative research; Re-challenge; Side effects; Statins

Mesh:

Substances:

Year:  2017        PMID: 28710589      PMCID: PMC6939993          DOI: 10.1007/s10557-017-6738-x

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  26 in total

1.  Using cognitive concept mapping to understand what health care means to the elderly: an illustrative approach for planning and marketing.

Authors:  Richard Shewchuk; Stephen J O'Connor
Journal:  Health Mark Q       Date:  2002

2.  Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.

Authors:  Robert L Ohsfeldt; Sanjay K Gandhi; Lee J Smolen; Marie M Jensen; Kathleen M Fox; Alex Gold; Judith Hsia
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

3.  Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention.

Authors:  Deborah A Levine; Kenneth G Saag; Linda L Casebeer; Cathleen Colon-Emeric; Kenneth W Lyles; Richard M Shewchuk
Journal:  J Am Med Dir Assoc       Date:  2006-07-17       Impact factor: 4.669

Review 4.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

Authors:  Rossana M Calderon; Luigi X Cubeddu; Ronald B Goldberg; Eugene R Schiff
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

5.  The nominal group as a research instrument for exploratory health studies.

Authors:  A H Van de Ven; A L Delbecq
Journal:  Am J Public Health       Date:  1972-03       Impact factor: 9.308

6.  Discontinuation of statins in routine care settings: a cohort study.

Authors:  Huabing Zhang; Jorge Plutzky; Stephen Skentzos; Fritha Morrison; Perry Mar; Maria Shubina; Alexander Turchin
Journal:  Ann Intern Med       Date:  2013-04-02       Impact factor: 25.391

7.  An assessment by the Statin Muscle Safety Task Force: 2014 update.

Authors:  Robert S Rosenson; Steven K Baker; Terry A Jacobson; Stephen L Kopecky; Beth A Parker
Journal:  J Clin Lipidol       Date:  2014 May-Jun       Impact factor: 4.766

Review 8.  The metabolic effects of exercise-induced muscle damage.

Authors:  W J Evans; J G Cannon
Journal:  Exerc Sport Sci Rev       Date:  1991       Impact factor: 6.230

9.  Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.

Authors:  Steven E Nissen; Erik Stroes; Ricardo E Dent-Acosta; Robert S Rosenson; Sam J Lehman; Naveed Sattar; David Preiss; Eric Bruckert; Richard Ceška; Norman Lepor; Christie M Ballantyne; Ioanna Gouni-Berthold; Mary Elliott; Danielle M Brennan; Scott M Wasserman; Ransi Somaratne; Rob Scott; Evan A Stein
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

10.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.

Authors:  Scott D Ramsey; Lauren D Clarke; Craig S Roberts; Sean D Sullivan; Scott J Johnson; Larry Z Liu
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more
  9 in total

1.  A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.

Authors:  Jingzhi Yu; Ann A Wang; Lindsay P Zimmerman; Yu Deng; Thanh-Huyen T Vu; Yacob G Tedla; Nicholas D Soulakis; Faraz S Ahmad; Abel N Kho
Journal:  J Gen Intern Med       Date:  2022-01-08       Impact factor: 6.473

2.  Risk assessment of atherosclerotic cardiovascular diseases before statin therapy initiation: Knowledge, attitude, and practice of physicians in Yemen.

Authors:  Fahmi Y Al-Ashwal; Syed Azhar Syed Sulaiman; Siti Maisharah Sheikh Ghadzi; Mohammed Abdullah Kubas; Abdulsalam Halboup
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

Review 3.  Statin-Associated Muscle Disease: Advances in Diagnosis and Management.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

4.  Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study).

Authors:  Matthew T Mefford; Gabriel S Tajeu; Rikki M Tanner; Lisandro D Colantonio; Keri L Monda; Ricardo Dent; Michael E Farkouh; Robert S Rosenson; Monika M Safford; Paul Muntner
Journal:  Am J Cardiol       Date:  2018-06-02       Impact factor: 3.133

Review 5.  Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis.

Authors:  Laney K Jones; Stephanie Tilberry; Christina Gregor; Lauren H Yaeger; Yirui Hu; Amy C Sturm; Terry L Seaton; Thomas J Waltz; Alanna K Rahm; Anne Goldberg; Ross C Brownson; Samuel S Gidding; Marc S Williams; Michael R Gionfriddo
Journal:  Implement Sci       Date:  2021-04-13       Impact factor: 7.327

6.  LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model.

Authors:  Laura Inglin; Piia Lavikainen; Kari Jalkanen; Tiina Laatikainen
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

7.  General practitioners' perspectives on the prevention of cardiovascular disease: systematic review and thematic synthesis of qualitative studies.

Authors:  Irene Ju; Emily Banks; Bianca Calabria; Angela Ju; Jason Agostino; Rosemary J Korda; Tim Usherwood; Karine Manera; Camilla S Hanson; Jonathan C Craig; Allison Tong
Journal:  BMJ Open       Date:  2018-11-01       Impact factor: 2.692

8.  Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription.

Authors:  Jeffrey D Clough; Seth S Martin; Ann Marie Navar; Li Lin; N Chantelle Hardy; Ursula Rogers; Lesley H Curtis
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

9.  Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care.

Authors:  Alexander Pate; Richard Emsley; Tjeerd van Staa
Journal:  Br J Gen Pract       Date:  2020-10-29       Impact factor: 5.386

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.